Mineralys Therapeutics Q3 2026 Earnings Date & Estimates

Mineralys Therapeutics (NASDAQ:MLYS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension. The company is also investigating the broader potential of aldosterone reduction in conditions involving cardiovascular and renal risk. Lorundrostat remains an investigational therapy and has not been approved for commercial use.

Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Mineralys conducts clinical development activities intended to support potential treatment applications in the United States and other markets. The company became publicly traded on the Nasdaq under the symbol MLYS in 2023. Mineralys is led by Chief Executive Officer Jon Congleton.